The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia

Alessandro Di Tullio; Kevin Rouault-Pierre; Ander Abarrategi; Syed Mian; William Grey; John Gribben; Aengus Stewart; Elizabeth Blackwood; Dominique Bonnet

doi:10.1038/s41467-017-01834-4

Nature Communications (Nov 2017)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia

Alessandro Di Tullio,
Kevin Rouault-Pierre,
Ander Abarrategi,
Syed Mian,
William Grey,
John Gribben,
Aengus Stewart,
Elizabeth Blackwood,
Dominique Bonnet

Affiliations

Alessandro Di Tullio: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute
Kevin Rouault-Pierre: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute
Ander Abarrategi: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute
Syed Mian: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute
William Grey: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute
John Gribben: Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Chaterhouse Square
Aengus Stewart: Bioinformatic Core, The Francis Crick Institute
Elizabeth Blackwood: Genentech, 1 DNA Way
Dominique Bonnet: Hematopoietic Stem Cell Laboratory, The Francis Crick Institute

DOI: https://doi.org/10.1038/s41467-017-01834-4
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 12

Abstract

Read online

Overriding cytarabine resistance in AML remains an unmet medical need. Here, the authors show that the CHK1 inhibitor GDC-0575 in combination with cytarabine and G-CSF has a significant anti-leukemic effect without toxicity to normal marrow stem and progenitor cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal